TESARO (TSRO) Given a $83.00 Price Target by Oppenheimer Analysts

Oppenheimer set a $83.00 target price on TESARO (NASDAQ:TSRO) in a report issued on Sunday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently commented on TSRO. BidaskClub upgraded TESARO from a buy rating to a strong-buy rating in a research report on Friday, October 19th. ValuEngine cut TESARO from a hold rating to a sell rating in a research report on Saturday, July 28th. Cowen reiterated a hold rating and set a $38.00 price target on shares of TESARO in a research report on Monday, October 22nd. Bank of America boosted their price target on TESARO from $38.00 to $39.00 and gave the stock a neutral rating in a research report on Friday, November 2nd. Finally, HC Wainwright dropped their price target on TESARO to $71.00 and set a buy rating for the company in a research report on Friday, July 20th. Nine research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock has a consensus rating of Buy and a consensus price target of $73.25.

Shares of TSRO opened at $25.99 on Friday. The company has a debt-to-equity ratio of 3.74, a current ratio of 3.40 and a quick ratio of 2.83. TESARO has a one year low of $23.41 and a one year high of $89.72. The company has a market cap of $1.49 billion, a P/E ratio of -2.83 and a beta of 1.35.

TESARO (NASDAQ:TSRO) last issued its quarterly earnings results on Thursday, November 1st. The biopharmaceutical company reported ($2.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($2.62) by $0.13. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The firm had revenue of $64.40 million during the quarter, compared to analysts’ expectations of $71.84 million. During the same period in the previous year, the business earned ($0.47) earnings per share. The firm’s revenue for the quarter was down 54.9% on a year-over-year basis. As a group, equities analysts predict that TESARO will post -10.97 EPS for the current year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Essex Investment Management Co. LLC acquired a new position in TESARO during the second quarter worth $733,000. ING Groep NV acquired a new position in shares of TESARO in the 2nd quarter valued at $667,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of TESARO by 49.9% in the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 136,441 shares of the biopharmaceutical company’s stock valued at $6,068,000 after purchasing an additional 45,450 shares during the last quarter. KBC Group NV lifted its stake in shares of TESARO by 20.0% in the 2nd quarter. KBC Group NV now owns 10,533 shares of the biopharmaceutical company’s stock valued at $468,000 after purchasing an additional 1,752 shares during the last quarter. Finally, Janney Montgomery Scott LLC acquired a new position in shares of TESARO in the 2nd quarter valued at $257,000.

About TESARO

Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting.

Featured Article: How to Invest in the Dividend Aristocrat Index

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply